US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi Beauty, Skincare & Aesthetics ETF

28.11

+0.03740.13%

Post-market: 28.110.00000.00%16:15 EDT

Volume:278

Turnover:8K

Market Cap:1.41M

PE:- -

High:28.11

Open:28.07

Low:28.11

Close:28.07

52wk High:29.89

52wk Low:24.32

Shares:50.00K

Float Shares:50.00K

Volume Ratio:1.70

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live

Align Technology Shares Fall After Evercore ISI Downgrade

MT Newswires Live

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Moderately bullish activity in Hims and Hers Health with shares up 3.07%

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS

Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

THOMSON REUTERS

Estee Lauder Raised to Overweight from Equal-Weight by Barclays

Align Slips as Brokerage Downgrades Rating to 'in Line' over Slowing Demand

Align Technology, Inc. : Evercore Isi Cuts to in Line from Outperform; Cuts Target Price to $155 from $220

THOMSON REUTERS

U.S. Stocks on the MOVE-Estée Lauder, PTC, Vaxcyte

Evercore ISI Downgrades Align Technology to In Line From Outperform

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/GLAM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GLAM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","market":"US","secType":"STK","nameCN":"Corgi Beauty, Skincare & Aesthetics ETF","latestPrice":28.1075,"timestamp":1791489600000,"preClose":28.0701,"halted":0,"volume":278,"hourTrading":{"tag":"盘后","latestPrice":28.1075,"preClose":28.1075,"latestTime":"16:15 EDT","volume":8,"amount":224.86,"timestamp":1791490500331,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0013323785807674948,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Post-Mkt","change":0.0374,"latestTime":"10-08 19:43:04 EDT","open":28.0701,"high":28.1075,"low":28.1075,"amount":7891,"amplitude":0,"askPrice":42.1,"askSize":200,"bidPrice":14.04,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791504000000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":28.0701,"nav":27.92,"aum":1396000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.1075,"preClose":28.1075,"latestTime":"16:15 EDT","volume":8,"amount":224.86,"timestamp":1791490500331,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.701348,"impliedVol":0.0781,"impliedVolPercentile":0.0808},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.701348,"shares":50000,"dividePrice":0,"high":28.1075,"amplitude":0,"preClose":28.0701,"low":28.1075,"week52Low":24.3178,"pbRate":"--","week52High":29.89,"institutionHeld":0,"latestPrice":28.1075,"eps":0,"divideRate":0,"volume":278,"delay":0,"ttmEps":0,"open":28.0701,"prevYearClose":25.82,"prevWeekClose":27.6182,"prevMonthClose":27.766,"prevQuarterClose":27.766,"fiveDayClose":27.5282,"twentyDayClose":27.7464,"sixtyDayClose":27.8939},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLAM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLAM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLAM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLAM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673081209","title":"AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081209","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081209?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:09","pubTimestamp":1791230948,"startTime":"0","endTime":"0","summary":"AbbVie cuts Q3 adjusted diluted EPS outlook to $3.73-$3.77 after $216 million acquired IPR&D, milestones expenseAbbVie cut Q3 2026 adjusted diluted EPS guidance to USD 3.73–3.77 from USD 3.84–3.88, re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDLbW9K2t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","BK4534","LU2023251221.USD","LU1934455863.HKD","GLAM","IE00BDGV0183.EUR","LU0122379950.USD","LU0170899867.USD","SG9999015978.USD","VHT","IE000BZT7R73.USD","LU0128525929.USD","ABBV","LU1267930573.SGD","IE00BGHQF631.EUR","IYH","LU0203345920.USD","LU0553294199.USD","LU1720051108.HKD","IE0004445239.USD","LU0234570918.USD","LU1162221912.USD","LU1430594728.SGD","BK4550","RXL","IE000SO60NU8.SGD","JDOC","TRUH","LU0158827948.USD","LU1037948541.HKD","MEDX","IE0002141913.USD","LU2237443978.SGD","XLV","LU1023059063.AUD","IE00B3PB1722.GBP","BK4588","AGNG","BK4566","PPH","LU0661504455.SGD","PJP","LU1732799900.SGD","LU0320765646.SGD","IXJ","LU1236620750.USD","FTXH","FHLC","LU1236620834.HKD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673812780","title":"Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673812780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673812780?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:08","pubTimestamp":1791230913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1JK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","BK4534","LU0128525929.USD","LU0234570918.USD","LU1162221912.USD","LU0158827948.USD","TRUH","LU1236620750.USD","AGNG","LU0320765646.SGD","RXL","VHT","IE000SO60NU8.SGD","FTXH","IYH","BK4550","LU1732799900.SGD","IE0002141913.USD","IXJ","LU1585245621.USD","IE0004445239.USD","LU0203345920.USD","MEDX","LU1720051108.HKD","LU0553294199.USD","LU2237443978.SGD","LU1934455863.HKD","LU0122379950.USD","LU2023251221.USD","PJP","PPH","IE00BGHQF631.EUR","IE00B3PB1722.GBP","IE000BZT7R73.USD","LU0170899867.USD","LU1236620834.HKD","BK4588","LU0661504455.SGD","LU1430594728.SGD","LU0943347566.SGD","FHLC","GLAM","SG9999015978.USD","LU1023059063.AUD","XLV","LU1037948541.HKD","JDOC","ABBV","IE00BDGV0183.EUR","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673220081","title":"Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673220081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673220081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:08","pubTimestamp":1791230913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PJP","RXL","TRUH","XLV","BK4534","IXJ","LU0823416689.USD","LU0661504455.SGD","BK4581","LU1244550577.SGD","PPH","AGNG","LU0203347892.USD","LU0689626769.HKD","IE00BGHQF631.EUR","LU0211327993.USD","LU0158827948.USD","LU2237443978.SGD","LU0553294199.USD","GLAM","FTXH","LU1496350502.SGD","LU0738911758.USD","ABBV","FHLC","LU0708994859.HKD","LU0795875086.SGD","LU2129689431.USD","LU2357305700.SGD","LU0795875169.SGD","LU0058720904.USD","LU1003077747.HKD","LU1061106388.HKD","LU0114720955.EUR","LU2087621335.USD","VHT","LU1585245621.USD","LU2237443895.HKD","LU0417517546.SGD","LU0545039389.USD","LU1267930573.SGD","BK4139","IE00BSNM7G36.USD","LU0912757837.SGD","IYH","LU1551013425.SGD","JDOC","LU1720051017.SGD","LU0124676726.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081273","title":"Abbvie Inc. Fy2026 Shr View $14.02","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081273?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:08","pubTimestamp":1791230913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1JK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1720051108.HKD","ABBV","GLAM","IXJ","SG9999015952.SGD","LU1093756168.USD","TRUH","SG9999003800.SGD","IE0004445239.USD","LU0859254822.USD","LU1718418525.SGD","LU1003077747.HKD","VHT","LU1983299246.USD","LU1732799900.SGD","LU0943347566.SGD","XLV","LU0057025933.USD","PPH","MEDX","RXL","LU0058720904.USD","IE00B3PB1722.GBP","BK4581","LU1061106388.HKD","FHLC","LU1923622614.USD","LU2125909593.SGD","LU0122379950.USD","LU1267930573.SGD","IYH","LU2237443549.SGD","LU1057294990.SGD","PJP","FTXH","LU2125909247.SGD","LU0417517546.SGD","LU1989772923.USD","AGNG","LU2237443622.USD","SG9999015978.USD","LU0203345920.USD","IE00BJT1NW94.SGD","LU2237443465.HKD","LU0098860793.USD","LU0256863902.USD","LU2347655073.USD","LU0965509010.AUD","LU0738911758.USD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081227","title":"Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081227?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:08","pubTimestamp":1791230913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1JK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237443382.USD","VHT","LU1496350502.SGD","SG9999015945.SGD","LU1718418525.SGD","LU1934455194.USD","AGNG","ABBV","LU2089283258.USD","LU2112291526.USD","SG9999001440.SGD","FHLC","LU0256863811.USD","GLAM","LU1074936037.SGD","BK4534","XLV","LU1236620750.USD","LU0949170772.SGD","LU2347655073.USD","IE00B19Z3B42.SGD","RXL","IE00BN8TJ469.HKD","LU0058720904.USD","LU2125909593.SGD","LU0170899867.USD","LU2237443622.USD","BK4581","LU0861579265.USD","LU0395794307.EUR","LU0689472784.USD","LU1244550221.USD","MEDX","PJP","IE00B3PB1722.GBP","IE00BLSP4452.SGD","LU2237443465.HKD","LU1839511570.USD","LU0511384066.AUD","TRUH","IYH","LU1929549753.HKD","LU0472753341.HKD","JDOC","PPH","FTXH","LU1037948897.HKD","IXJ","LU0289961442.SGD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673819760","title":"Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673819760","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673819760?lang=en_us&edition=fundamental","pubTime":"2026-10-06 03:50","pubTimestamp":1791229824,"startTime":"0","endTime":"0","summary":"Genmab  and AbbVie  said that adding their drug epcoritamab to a standard chemotherapy mix helped people with an aggressive form of blood cancer stay cancer-free longer than chemotherapy alone.The combination cut the risk of the cancer getting worse or the patient dying by 51% compared with standard treatment alone, the companies said Monday in a statement. Results were from a large study in newly diagnosed patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.The treatment paired epcoritamab with R-CHOP, a long-used chemotherapy regimen. The companies said the safety of the combination looked generally similar to what doctors already expect from each drug on its own.Because the treatment is still experimental, Genmab and AbbVie plan to meet with regulators around the world to discuss next steps.Genmab shares rose 11% in Monday trading, and AbbVie gained 1.3%.Price: 38.72, Change: +3.97, Percent Change: +11.41","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2089283258.USD","GMAB","IE00BN8TJ469.HKD","LU2347655156.SGD","IE00BSNM7G36.USD","VHT","LU0256863811.USD","LU0158827948.USD","IYH","SG9999003800.SGD","RXL","BK4581","ABBV","IE00B4R5TH58.HKD","LU1839511570.USD","TRUH","FHLC","LU2237443465.HKD","LU0942090050.USD","LU0689626769.HKD","GLAM","LU0795875169.SGD","MEDX","LU2237443382.USD","LU0965509101.SGD","LU1989772840.SGD","LU1057294990.SGD","FTXH","LU0859254822.USD","LU2125909593.SGD","LU1923622614.USD","LU1244550221.USD","LU0395794307.EUR","LU2347655073.USD","SG9999015945.SGD","PJP","XLV","JDOC","IE000MB6IJN5.SGD","IXJ","IE00BVYPNW00.USD","LU2089284900.SGD","AGNG","IE00BLSP4239.USD","LU1162221912.USD","LU0128525929.USD","PPH","LU2237443549.SGD","LU1983299246.USD","LU2129689605.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673815430","title":"Align Technology Shares Fall After Evercore ISI Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2673815430","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673815430?lang=en_us&edition=fundamental","pubTime":"2026-10-06 03:49","pubTimestamp":1791229798,"startTime":"0","endTime":"0","summary":"Align Technology  shares were down about 1.9% in Monday trading after Evercore ISI downgraded the stock to in-line from outperform and cut its price target to $155 from $220.Intraday trading volume was more than 1.2 million shares, compared with a daily average of about 891,000.Price: 141.06, Change: -2.68, Percent Change: -1.86","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALGN","LU1974910355.USD","BK4534","BK4585","LU2106854487.HKD","LU2023250504.SGD","BK4198","BK4504","BK4588","GLAM","LU1917777945.USD","LU2023250843.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673811030","title":"Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2673811030","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673811030?lang=en_us&edition=fundamental","pubTime":"2026-10-06 03:47","pubTimestamp":1791229638,"startTime":"0","endTime":"0","summary":"An announcement from Genmab ( ($GMAB) ) is now available. Genmab and AbbVie reported on October 5, 2026, that their Phase 3 EPCORE DLBCL-2 trial sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genmab-and-abbvie-report-landmark-phase-3-win-for-epcoritamab-combo-in-frontline-dlbcl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genmab-and-abbvie-report-landmark-phase-3-win-for-epcoritamab-combo-in-frontline-dlbcl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000SO60NU8.SGD","IE00B3PB1722.GBP","LU0823416689.USD","IE00B4R5TH58.HKD","LU2089284900.SGD","LU1718418525.SGD","BK4559","PPH","LU0158827948.USD","LU0689626769.HKD","BK4581","TRUH","LU0965509101.SGD","IE000F7OJYX1.SGD","LU1720051017.SGD","BK4550","IE00BDGV0183.EUR","LU0965509283.SGD","LU1037948541.HKD","LU1670628061.USD","MEDX","LU2357305700.SGD","JDOC","RXL","FHLC","LU2468319806.SGD","LU1496350502.SGD","IYH","BK4585","LU2237443382.USD","LU1244550221.USD","VHT","FTXH","AGNG","PJP","LU0122379950.USD","GLAM","ABBV","XLV","LU1236620750.USD","LU1929549753.HKD","LU2237443978.SGD","LU1037948897.HKD","BK4588","LU1074936037.SGD","LU0456855351.SGD","LU0289739699.SGD","LU1551013342.USD","LU2237443465.HKD","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673363081","title":"AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673363081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673363081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 03:36","pubTimestamp":1791228977,"startTime":"0","endTime":"0","summary":"AbbVie blood cancer drug combo cuts risk of progression or death in late-stage studyOct 5 (Reuters)-Danish biotech firm GenmabGMAB.COand US drugmaker AbbVieABBV.Nsaid on Monday their combination treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R185:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU2237443549.SGD","JDOC","LU1983299246.USD","LU2089284900.SGD","GLAM","LU0158827948.USD","IE000MB6IJN5.SGD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU1244550221.USD","LU0942090050.USD","IE00BLSP4239.USD","IXJ","AGNG","TRUH","IE00BVYPNW00.USD","LU2347655156.SGD","LU1989772840.SGD","LU2237443465.HKD","ABBV","IYH","LU0128525929.USD","LU2125909593.SGD","PJP","RXL","VHT","LU1839511570.USD","BK4581","LU0795875169.SGD","LU1057294990.SGD","LU1923622614.USD","IE00BSNM7G36.USD","LU0965509101.SGD","PPH","LU2129689605.HKD","LU2089283258.USD","LU0689626769.HKD","IE00B4R5TH58.HKD","LU0859254822.USD","LU0395794307.EUR","FTXH","LU2347655073.USD","XLV","SG9999003800.SGD","LU2237443382.USD","IE00BN8TJ469.HKD","LU1162221912.USD","SG9999015945.SGD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673311081","title":"Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673311081","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673311081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:55","pubTimestamp":1791226515,"startTime":"0","endTime":"0","summary":"Genmab A/S (GMAB) and AbbVie (ABBV) announced “positive” topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genmab-abbvie-report-epcoritamab-combination-demonstrates-improved-pfs-in-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genmab-abbvie-report-epcoritamab-combination-demonstrates-improved-pfs-in-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPH","VHT","LU1934455277.USD","IE00BJT1NW94.SGD","LU0128525929.USD","GLAM","LU0511384066.AUD","FTXH","LU1267930490.SGD","MEDX","LU0417517546.SGD","LU2125909593.SGD","GMAB","LU2023251221.USD","LU1023059063.AUD","LU0868494617.USD","LU1496350171.SGD","LU0395794307.EUR","LU1074936037.SGD","LVIG","LU2087621335.USD","IE000MB6IJN5.SGD","LU1934455194.USD","FHLC","SG9999001440.SGD","ABBV","LU0726765562.USD","LU2433249047.HKD","LU0058720904.USD","PJP","LU2357627491.SGD","IXJ","LU2089284900.SGD","XLV","LU0069063385.USD","TRUH","LU0256863902.USD","LU1720051108.HKD","JDOC","IYH","LU1585245621.USD","AGNG","LU0211328371.USD","LU0203345920.USD","LU0456855351.SGD","LU1551013342.USD","LU0289739699.SGD","LU0057025933.USD","SG9999015986.USD","RXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089429","title":"Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089429","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089429?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:50","pubTimestamp":1791226259,"startTime":"0","endTime":"0","summary":"Genmab says Phase 3 EPCORE DLBCL-2 trial shows epcoritamab plus R-CHOP cuts progression or death risk 51% in newly diagnosed DLBCLGenmab, AbbVie reported positive topline Phase 3 results for epcoritam","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDLWBPbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BK4588","AGNG","NDAQ","IE000WAW04H5.SGD","LU0158827948.USD","MEDX","FTXH","BCDF","LU2468319806.SGD","IE00BJT1NW94.SGD","LU1003077747.HKD","TRUH","LU0234570918.USD","LU0198837287.USD","IE000SO60NU8.SGD","LU0882574055.USD","BK4581","VHT","ABBV","IE00B19Z3581.USD","LU2095319765.USD","LU0859254822.USD","FHLC","LU1023059063.AUD","LU1989771016.USD","LU0114720955.EUR","LU0912757837.SGD","LU0320765646.SGD","LU1585245621.USD","IXJ","XLV","BK4550","IE00B2B36J28.USD","GLAM","JDOC","IYH","IE00B19Z3B42.SGD","PJP","IE00BN0W2V16.EUR","LU1720051017.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2089283258.USD","LU1923622614.USD","PPH","LU0943347566.SGD","RXL","LU0310799852.SGD","LU0289961442.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081372","title":"Moderately bullish activity in Hims and Hers Health with shares up 3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081372?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:50","pubTimestamp":1791226213,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Hims and Hers Health (HIMS), with shares up 89c, or 3.07%, near $29.89. Options volume roughly in line with average ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-hims-and-hers-health-with-shares-up-3-07-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-hims-and-hers-health-with-shares-up-3-07-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HIYY","HIMS","HIMC","HIMY","HMYY","THNR","HIMZ","HEAL","GLAM","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673894940","title":"Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2673894940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673894940?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:49","pubTimestamp":1791226144,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1GV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1989771016.USD","BK4550","GLAM","IE000SO60NU8.SGD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU1003077747.HKD","LU2468319806.SGD","FHLC","IYH","LU0943347566.SGD","LU0198837287.USD","LU0553294199.USD","LU0289961442.SGD","LU0320765646.SGD","IE00B2B36J28.USD","BK4588","FTXH","LU0310799852.SGD","BK4581","IE0000B7K699.USD","LU0912757837.SGD","LU1585245621.USD","MEDX","LU0158827948.USD","IE00B19Z3581.USD","LU1023059063.AUD","XLV","LU1720051017.SGD","LU0882574055.USD","ABBV","LU1267930573.SGD","JDOC","IXJ","TRUH","LU0965509010.AUD","PPH","RXL","PJP","LU1551013425.SGD","VHT","LU1923622614.USD","AGNG","IE000WAW04H5.SGD","IE00BJT1NW94.SGD","LU0456855351.SGD","LU0859254822.USD","LU2089283258.USD","LU0234570918.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673894110","title":"Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2673894110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673894110?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:49","pubTimestamp":1791226144,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1GV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1244550577.SGD","GLAM","LU0738911758.USD","BK4559","LU1551013425.SGD","LU0949170772.SGD","LU0708994859.HKD","LU1934455194.USD","LU1989772923.USD","XLV","RXL","LU0256863811.USD","LU2129689605.HKD","LU0868494617.USD","MEDX","PJP","LU0256863902.USD","LU0861579265.USD","SG9999015952.SGD","LU2237443382.USD","IE00BVYPNV92.GBP","LU1037948541.HKD","LU0417517546.SGD","LU0795875169.SGD","FTXH","LU0128525929.USD","FHLC","IE00BJT1NW94.SGD","BK4566","AGNG","LU0234570918.USD","LU2357627491.SGD","LU1548497426.USD","LU0689626769.HKD","JDOC","BK4534","VHT","LU1934455277.USD","LU0965509101.SGD","LU0795875086.SGD","PPH","IE0004445239.USD","TRUH","LU2023251221.USD","BK4550","IXJ","IYH","LU0456855351.SGD","ABBV","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089491","title":"Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089491?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:49","pubTimestamp":1791226144,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0868494617.USD","MEDX","VHT","LU1934455863.HKD","IYH","JDOC","LU0320765646.SGD","FHLC","LU2112291526.USD","LU2433249047.HKD","TRUH","LU1923622614.USD","LU2129689605.HKD","IE00BVYPNW00.USD","IXJ","LU0820561909.HKD","LU1989772840.SGD","PJP","LU0689472784.USD","PPH","LU1934455277.USD","LU0823416689.USD","LU2089284900.SGD","BK4585","LU2089984988.USD","LU1267930573.SGD","LU1720051108.HKD","RXL","ABBV","LU1585245621.USD","GLAM","FTXH","IE00B19Z3B42.SGD","LU1037948897.HKD","IE000SO60NU8.SGD","LU2129689514.USD","XLV","LU0511384066.AUD","LU2237443382.USD","LU2087621335.USD","LU1267930490.SGD","LU1023059063.AUD","LU1236620750.USD","IE00B3PB1722.GBP","LU0965509101.SGD","LU1093756168.USD","LU1551013342.USD","AGNG","LU0868494708.USD","IE000BZT7R73.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673091707","title":"Estee Lauder Raised to Overweight from Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673091707","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673091707?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:59","pubTimestamp":1791205140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EL/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2552382132.HKD","BK4548","BK4588","GLAM","LU2552382058.USD","EL","LU2552382215.SGD","LU0690374961.EUR","BK4183","BK4533","BK4585","LU2404859741.USD","LU2264538146.SGD","BK4558","LU1064131342.USD","LU2404859667.USD","BK4504","LU0690374615.EUR","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673970407","title":"Align Slips as Brokerage Downgrades Rating to 'in Line' over Slowing Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2673970407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673970407?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:37","pubTimestamp":1791200244,"startTime":"0","endTime":"0","summary":"BUZZ-Align slips as brokerage downgrades rating to 'in line' over slowing demand** Shares of Align TechnologyALGN.Ofall 3% to $139.45 premarket** Brokerage Evercore ISI cuts ALGN's rating to \"in line\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R0NV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLAM","BK4585","BK4588","BK4127","ALGN","BK4504","BK4534","BK4198","LU1917777945.USD","LU2023250504.SGD","LU1974910355.USD","LU2106854487.HKD","LU2023250843.SGD","EVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673770110","title":"Align Technology, Inc. : Evercore Isi Cuts to in Line from Outperform; Cuts Target Price to $155 from $220","url":"https://stock-news.laohu8.com/highlight/detail?id=2673770110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673770110?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:45","pubTimestamp":1791197121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALGN","LU2106854487.HKD","LU1974910355.USD","BK4585","BK4534","BK4504","GLAM","LU2023250504.SGD","BK4198","LU1917777945.USD","LU2023250843.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673013957","title":"U.S. Stocks on the MOVE-Estée Lauder, PTC, Vaxcyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2673013957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673013957?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:30","pubTimestamp":1791196242,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, PTC, VaxcyteOct 5 -U.S. stock index futures dipped on Monday, as technology stocks took a breather after touching record highs, while investors looked for fresh clues on the monetary policy path with Treasury yields and oil prices still elevated..N** VaxcytePCVX.O:BUZZ - Vaxcyte surges on pneumococcal vaccine late-stage trial successnL4N45R0K0** Estée LauderEL.N:BUZZ - Estée Lauder up after Barclays upgrades to 'overweight'nL6N45R0HX** PTCPTC.O:BUZZ - PTC surges after Schneider Electric agrees to $22.6 bln buyout dealnL6N45R0HV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL6N4500LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0950375773.USD","LU2506952337.HKD","PCVX","LU2264538146.SGD","LU2362541273.HKD","BK4139","SG9999014013.SGD","LU0690374615.EUR","BK4554","LU2362540622.SGD","LU1951198990.SGD","LU2362541513.USD","LU0053671581.USD","LU2506952410.USD","LU1988902786.USD","BK4558","LU2506951875.HKD","BK4183","LU2404859667.USD","LU2477742899.HKD","LU2552382058.USD","LU1721428347.USD","SG9999014021.USD","LU2506952097.USD","LU1064131342.USD","LU2552382132.HKD","LU0690374961.EUR","LU0823417653.USD","LU1923623000.USD","BK4548","BK4588","LU2506952170.USD","BK4023","SG9999014005.SGD","PTC","IE0009354923.USD","BK4533","GLAM","LU2506951958.HKD","BK4504","LU2404859741.USD","BK4576","LU1951200564.SGD","LU0823417737.USD","BK4585","EL","LU2552382215.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673706062","title":"Evercore ISI Downgrades Align Technology to In Line From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2673706062","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673706062?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:47","pubTimestamp":1791193667,"startTime":"0","endTime":"0","summary":"Align Technology (ALGN) has an average rating of overweight and mean price target of $207.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALGN","LU2106854487.HKD","LU1974910355.USD","BK4585","BK4534","BK4504","GLAM","LU2023250504.SGD","BK4198","LU1917777945.USD","LU2023250843.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}